PRTA - Mergers and acquisitions

Net cash provided by operating and investing activities was $111.9 million in the third quarter and $114.8 million for the first nine months of 2021; Quarter-end cash and restricted cash position was $601.5 million Received $140 million from partner payments in third quarter from Novo Nordisk and Bristol Myers SquibbAnnounced two key executive appointments to support transition to a fully integrated biotechnology company DUBLIN, Ireland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third q

Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars, including 100 million dollars in upfront and near-term clinical milestone paymentsNovo Nordisk will develop the phase 2 ready antibody PRX004 for the rare heart disease ATTR cardiomyopathy DUBLIN, Ireland and BAGSVÆRD, Denmark, July 12, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) and Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) today announced that the companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena's clinical stage antibody PRX004 and broader ATTR amyloidosis programme. PRX004 is a phase 2 ready an